Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Use of Duloxetine or Pregabalin in Monotherapy versus Combination Therapy of Both Drugs in Patients with Painful Diabetic Neuropathy "The COMBO - DN (Combination vs Monotherapy of pregaBalin and dulOxetine in Diabetic Neuropathy) Study"

Trial Profile

Use of Duloxetine or Pregabalin in Monotherapy versus Combination Therapy of Both Drugs in Patients with Painful Diabetic Neuropathy "The COMBO - DN (Combination vs Monotherapy of pregaBalin and dulOxetine in Diabetic Neuropathy) Study"

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Duloxetine (Primary) ; Pregabalin (Primary)
  • Indications Diabetic neuropathies; Neuropathic pain
  • Focus Therapeutic Use
  • Acronyms COMBO-DN; HMGQ
  • Sponsors Eli Lilly and Company
  • Most Recent Events

    • 05 Oct 2012 Results from duloxetine monotherapy versus pregabalin monotherapy analysis presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
    • 31 Aug 2012 Results presented at the 14th World Congress on Pain.
    • 15 Mar 2012 This trial is recruting in England, Sweden, Spain, France as reported by European Clinical Trials Database.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top